Synlogic announces first industry collaboration with AbbVie to develop a new class of medicines designed to power the microbiome
![](/46/pdcnewsitem/03/90/45/synlogic.png)
Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease.
Synlogic has signed a multi-year global R&D collaboration with AbbVie. The collaboration is focused on developing novel medicines for the treatment of inflammatory bowel disease (IBD) using Synlogic’s proprietary approach for a new class of synthetic biotic medicines that power the microbiome.
Under the terms of the collaboration, Synlogic will discover, characterize and optimize synthetic biotics-based drug candidates through an R&D program covering a limited number of effectors modulating the IBD pathophysiology, with special emphasis on Crohn’s disease and ulcerative colitis. One of the goals of the multi-year collaboration is to combine AbbVie’s expertise in metabolic and inflammatory diseases with Synlogic’s platform to generate and advance to the clinic a novel, oral probiotic therapeutic candidate. Using Synlogic’s synthetic biotics platform, the novel probiotic drug candidate will be designed with synthetic programmable genetic circuits that can blend with the patient’s microbiome and perform a programmed therapeutic operation involved in the IBD disease process.
“Synlogic’s innovative approach to targeting the microbiome offers a new way to address inflammatory bowel disease,” said Jim Sullivan, vice president, pharmaceutical discovery, AbbVie. “AbbVie is committed to collaborating with scientific leaders with new technologies and therapeutic advances that complement AbbVie’s internal expertise and share our commitment to advancing the standard of care for patients.”
Under the R&D collaboration, AbbVie and Synlogic will evaluate synthetic biotic candidates that modulate certain effectors involved in the IBD pathway and advance them through preclinical development, with AbbVie being responsible for regulatory filings, clinical development and worldwide marketing of any resulting products. Financial terms were not disclosed.
“We are delighted to be working with AbbVie, an innovative leader in treating inflammation and autoimmune diseases. We envision the potential for strong synergy from the combination of AbbVie’s metabolic and inflammation expertise with our novel therapeutic approach of precision programing in the microbiome, opening new ways to create synthetic biotics to address the significant unmet needs for people with IBD,” said Jose-Carlos (JC) Gutiérrez-Ramos, CEO of Synlogic. “This partnership with AbbVie is a part of our overall strategy for enabling the broad potential of our synthetic biotics platform by forging partnerships with pharmaceutical and biotechnology leaders to pursue major disease indications affecting millions of patients, while simultaneously accelerating Synlogic’s internal pipeline in rare orphan diseases toward the clinic.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance